Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271321 | 0.98 | PPARD (0.69) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3271323 | 0.98 | PPARD (0.69) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3274129 | 0.89 | PPARD (0.75) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3274126 | 0.89 | PPARD (0.75) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3270949 | 0.89 | PPARD (0.71) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3271322 | 0.89 | PPARD (0.53) | PPARDTDP1PPARAPTGDR2 | |
| SCHEMBL3273384 | 0.88 | PPARD (0.80) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3269414 | 0.87 | PPARD (0.57) | PPARDTDP1TSHRPPARAPTGDR2 | |
| SCHEMBL3269540 | 0.87 | PPARD (0.69) | PPARDTDP1TSHRCYP2C19PPARA | |
| SCHEMBL3271335 | 0.87 | PPARD (0.72) | PPARDTDP1TSHRCYP2C19PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | claimed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | claimed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | claimed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885TDP1 3789/4885TSHR 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.